Table S5.
Western blot analysis of protein transcription in ZER-NLC-treated Jurkat cells
| Proteins | Control | 24 hours | 48 hours | 72 hours |
|---|---|---|---|---|
| Protein transcription level (%) | ||||
| Bax | 21.29 | 36.11* | 44.32* | 57.19* |
| Bcl-2 | 55.90 | 32.75** | 25.54** | 18.55** |
| Cyt-c | 17.61 | 25.23* | 33.45* | 45.78* |
| PARP | 22.02 | 31.20* | 43.98* | 54.11* |
| Cyclin B1 | 48.54 | 35.23** | 24.14** | 16.34** |
Notes: Values are expressed as the mean ± standard deviation of three different experiments. The data were analyzed using post hoc comparison test-one way analysis of variance, with means compared by Tukey’s b test.
*
Significant (P<0.05) upregulation of protein in the ZER-NLC-treated group versus untreated control.
**
Significant (P<0.05) downregulation of protein in ZER-NLC-treated group versus untreated control.
Abbreviations: PARP, poly(adenosine diphosphate-ribose) polymerase; ZER-NLC, zerumbone-loaded nanostructured lipid carrier; Bcl-2, B cell lymphoma 2; Bax, Bcl-2 associated X protein; Cyt-c, cytochrome c.